Logo image of BEAM

BEAM THERAPEUTICS INC (BEAM) Stock Fundamental Analysis

USA - NASDAQ:BEAM - US07373V1052 - Common Stock

21.87 USD
-0.61 (-2.71%)
Last: 11/12/2025, 5:40:36 PM
22.3 USD
+0.43 (+1.97%)
After Hours: 11/12/2025, 5:40:36 PM
Fundamental Rating

3

Overall BEAM gets a fundamental rating of 3 out of 10. We evaluated BEAM against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, BEAM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BEAM had negative earnings in the past year.
BEAM had a negative operating cash flow in the past year.
BEAM had negative earnings in each of the past 5 years.
In the past 5 years BEAM reported 4 times negative operating cash flow.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

BEAM has a Return On Assets of -31.63%. This is in the better half of the industry: BEAM outperforms 65.72% of its industry peers.
With a decent Return On Equity value of -42.92%, BEAM is doing good in the industry, outperforming 69.68% of the companies in the same industry.
Industry RankSector Rank
ROA -31.63%
ROE -42.92%
ROIC N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

BEAM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K

More info and screens

7

2. Health

2.1 Basic Checks

BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BEAM has been increased compared to 1 year ago.
Compared to 5 years ago, BEAM has more shares outstanding
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of 1.64, we must say that BEAM is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.64, BEAM is doing good in the industry, outperforming 65.91% of the companies in the same industry.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.64
ROIC/WACCN/A
WACC8.77%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

BEAM has a Current Ratio of 6.02. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
BEAM's Current ratio of 6.02 is fine compared to the rest of the industry. BEAM outperforms 64.22% of its industry peers.
A Quick Ratio of 6.02 indicates that BEAM has no problem at all paying its short term obligations.
BEAM's Quick ratio of 6.02 is fine compared to the rest of the industry. BEAM outperforms 64.97% of its industry peers.
Industry RankSector Rank
Current Ratio 6.02
Quick Ratio 6.02
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BEAM have decreased strongly by -151.70% in the last year.
Looking at the last year, BEAM shows a very negative growth in Revenue. The Revenue has decreased by -84.07% in the last year.
Measured over the past years, BEAM shows a very strong growth in Revenue. The Revenue has been growing by 401.62% on average per year.
EPS 1Y (TTM)-151.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.98%
Revenue 1Y (TTM)-84.07%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-32.03%

3.2 Future

The Earnings Per Share is expected to grow by 7.39% on average over the next years.
Based on estimates for the next years, BEAM will show a very strong growth in Revenue. The Revenue will grow by 54.27% on average per year.
EPS Next Y3.42%
EPS Next 2Y0.74%
EPS Next 3Y-1.15%
EPS Next 5Y7.39%
Revenue Next Year-18.5%
Revenue Next 2Y-1.51%
Revenue Next 3Y4.9%
Revenue Next 5Y54.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BEAM. In the last year negative earnings were reported.
Also next year BEAM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.74%
EPS Next 3Y-1.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BEAM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAM THERAPEUTICS INC

NASDAQ:BEAM (11/12/2025, 5:40:36 PM)

After market: 22.3 +0.43 (+1.97%)

21.87

-0.61 (-2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners105.17%
Inst Owner Change-0.12%
Ins Owners1.21%
Ins Owner Change-0.13%
Market Cap2.21B
Revenue(TTM)55.70M
Net Income(TTM)-414.64M
Analysts86.36
Price Target46.63 (113.21%)
Short Float %20.45%
Short Ratio7.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.96%
Min EPS beat(2)-3.72%
Max EPS beat(2)11.65%
EPS beat(4)2
Avg EPS beat(4)4.61%
Min EPS beat(4)-3.72%
Max EPS beat(4)11.65%
EPS beat(8)6
Avg EPS beat(8)38.34%
EPS beat(12)10
Avg EPS beat(12)33.96%
EPS beat(16)13
Avg EPS beat(16)27.04%
Revenue beat(2)0
Avg Revenue beat(2)-31.11%
Min Revenue beat(2)-38.81%
Max Revenue beat(2)-23.41%
Revenue beat(4)1
Avg Revenue beat(4)-9.71%
Min Revenue beat(4)-50.74%
Max Revenue beat(4)74.11%
Revenue beat(8)2
Avg Revenue beat(8)180.25%
Revenue beat(12)5
Avg Revenue beat(12)131.05%
Revenue beat(16)9
Avg Revenue beat(16)242.98%
PT rev (1m)1.97%
PT rev (3m)4.4%
EPS NQ rev (1m)-0.57%
EPS NQ rev (3m)6.55%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)5.44%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-16.4%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-19.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.72
P/FCF N/A
P/OCF N/A
P/B 2.29
P/tB 2.29
EV/EBITDA N/A
EPS(TTM)-4.43
EYN/A
EPS(NY)-4.51
Fwd EYN/A
FCF(TTM)-3.48
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS0.55
BVpS9.55
TBVpS9.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.63%
ROE -42.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.26%
Cap/Sales 25.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.02
Quick Ratio 6.02
Altman-Z 1.64
F-Score3
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)185.1%
Cap/Depr(5y)305.75%
Cap/Sales(3y)34.46%
Cap/Sales(5y)16398.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-151.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.98%
EPS Next Y3.42%
EPS Next 2Y0.74%
EPS Next 3Y-1.15%
EPS Next 5Y7.39%
Revenue 1Y (TTM)-84.07%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-32.03%
Revenue Next Year-18.5%
Revenue Next 2Y-1.51%
Revenue Next 3Y4.9%
Revenue Next 5Y54.27%
EBIT growth 1Y-155.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.51%
EBIT Next 3Y-6.86%
EBIT Next 5Y8.74%
FCF growth 1Y10.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.33%
OCF growth 3YN/A
OCF growth 5YN/A

BEAM THERAPEUTICS INC / BEAM FAQ

What is the ChartMill fundamental rating of BEAM THERAPEUTICS INC (BEAM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BEAM.


What is the valuation status of BEAM THERAPEUTICS INC (BEAM) stock?

ChartMill assigns a valuation rating of 0 / 10 to BEAM THERAPEUTICS INC (BEAM). This can be considered as Overvalued.


Can you provide the profitability details for BEAM THERAPEUTICS INC?

BEAM THERAPEUTICS INC (BEAM) has a profitability rating of 1 / 10.